Evidence map›Paper›PMID 27531690›Full record

ArticleJournal of postgraduate medicine

Do high sensitivity C-reactive protein and serum interleukin-6 levels correlate with disease activity in systemic lupus erythematosuspatients?

V Umare, A Nadkarni, M Nadkar, A Rajadhyksha, P Khadilkar, K Ghosh, V D Pradhan

Open access · diamondAbstract read
In one paragraph

Article in Journal of postgraduate medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020
    Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

V UmareDepartment of Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, Maharashtra, India.
A NadkarniDepartment of Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, Maharashtra, India.
M NadkarDepartment of Medicine, King Edward Memorial Hospital, Mumbai, Maharashtra, India.
A RajadhykshaDepartment of Medicine, King Edward Memorial Hospital, Mumbai, Maharashtra, India.
P KhadilkarDepartment of Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, Maharashtra, India.
K GhoshDepartment of Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, Maharashtra, India.
V D PradhanDepartment of Clinical and Experimental Immunology, National Institute of Immunohaematology, Indian Council of Medical Research, Mumbai, Maharashtra, India.
Indian Council of Medical Research · INKing Edward Memorial Hospital Research Centre · INNational Institute of Immunohaematology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSystemic Lupus Erythematosus (SLE) is an inflammatory autoimmune disease where an interplay between acute phase proteins and cytokines are involved in disease activation. AIM AND

objectivesThis case control study was performed to investigate interrelationship between high sensitivity C-reactive proteins (hs-CRP), Interleukin-6 (IL-6) levels and disease activity among SLE patients. MATERIALS AND

methodsOne hundred forty one clinically diagnosed SLE cases were included and disease activity was noted by SLE Disease Activity Index (SLEDAI). Serum IL-6 levels were measure by cytokine multiplex assay. Serum hs-CRP, C3 and C4 levels were measure by nephelometer. The Pearson correlation test was used for correlation between hs-CRP, Il-6 and SLEDAI.

resultsBased on SLEDAI, 126 patients (89.4 %) had active disease and 15 patients (10.6%) had inactive disease. Mean hs-CRP levels in SLE patients were significantly higher (12.1+ 11.5 mg/L) than controls (2.41+ 1.37 mg/L) (P < 0.0001). Hs-CRP levels among active SLE were significantly higher (13.5+ 11.4 mg/L) as compared with inactive SLE (4.4 + 2.9 mg/L) (P=0.0002). Similarly, IL-6 levels in SLE patients were significantly higher among active SLE (26.9 + 15.5 pg/ml) as compared with inactive SLE (13.9+ 10.2 pg/ml) (P=0.0001). An inverse correlation between Il-6 and hemoglobin levels between active and inactive SLE was noted (r=-0.46, P <0.0001).

conclusionThis study suggests a good correlation between hs-CRP, IL-6 and SLE disease activity indicating their direct involvement in inflammatory conditions associated with disease.

Indexed as

Severity of Illness IndexAdolescentAdultBiomarkersCase-Control StudiesC-Reactive ProteinFemaleHumansInterleukin-6Lupus Erythematosus, SystemicMaleMiddle AgedNephelometry and TurbidimetryYoung AdultBiomarkersC-Reactive ProteinInterleukin-6

Identifiers

PMID27531690
PMCPMC5414434
OpenAlexW2507157566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.